Identification of Highly Efficacious Glucocorticoid Receptor Agonists with a Potential for Reduced Clinical Bone Side Effects
Citations Over TimeTop 10% of 2014 papers
Abstract
Synthesis and structure-activity relationship (SAR) of a series of nonsteroidal glucocorticoid receptor (GR) agonists are described. These compounds contain "diazaindole" moieties and display different transcriptional regulatory profiles in vitro and are considered "dissociated" between gene transrepression and transactivation. The lead optimization effort described in this article focused in particular on limiting the transactivation of genes which result in bone side effects and these were assessed in vitro in MG-63 osteosarcoma cells, leading to the identification of (R)-18 and (R)-21. These compounds maintained anti-inflammatory activity in vivo in collagen induced arthritis studies in mouse but had reduced effects on bone relevant parameters compared to the widely used synthetic glucocorticoid prednisolone 2 in vivo. To our knowledge, we are the first to report on selective glucocorticoid ligands with reduced bone loss in a preclinical in vivo model.
Related Papers
- → The role of the glucocorticoid receptor and its impact on steroid response in moderate-severe COVID-19 patients(2023)6 cited
- → Heterogeneity of Binding Sites for Glucocorticoid and the Glucocorticoid-Receptor Complex in Rat Livers(1984)1 cited
- [Medicinal activation and inhibition of function of glucocorticoid receptors as the basis for regulation of the glucocorticoid effect].(1994)
- → Giucocorticoid-Insensitive Bronchial Asthma(2008)
- Study on the Relationship Between Sensitivity to Glucocorticoid and Glucocorticoid Receptor Isoform in Patients with Idiopathic Thrombocytopenia Purpura(2007)